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a  b  s  t  r  a  c  t
Positron emission tomography (PET) with 18F-ﬂuorodeoxyglucose (FDG) is a valuable tool
for  diagnosing and staging malignant lesions. The fusion of PET and computed tomogra-
phy  (CT) yields images that contain both metabolic and morphological information, which,
taken together, have improved the diagnostic precision of PET in oncology. The main imag-
ing  modality for planning radiotherapy treatment is CT. However, PET-CT is an emerging
modality for use in planning treatments because it allows for more  accurate treatment vol-
ume  deﬁnition. The use of PET-CT for treatment planning is highly complex, and protocols
and standards for its use are still being developed. It seems probable that PET-CT will even-
tually replace current CT-based planning methods, but this will require a full understandingDelineation
Contouring
of  the relevant technical aspects of PET-CT planning. The aim of the present document is
to  review these technical aspects and to provide recommendations for clinical use of this
imaging modality in the r
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.  Introduction
.1.  The  radiotherapy  process
adiotherapy (RT) has long played an important role in treating
nd curing cancer. The effectiveness of RT is dose-dependent:
he higher the dose and the larger the volume irradiated, the
reater the probability of controlling the cancer. However, as
he dose increases, so does the likelihood of damaging healthy
issues. For this reason, the aim of treatment is to maximize
he dose delivered to the tumour while preserving, to the
xtent possible, adjacent healthy tissue. In short, like other
reatments, the aim is to achieve the highest cure rate with
he fewest side effects.
Radiotherapy treatment is a complex process involving a
eries of sequential steps that make up what is known as
he radiotherapy process. In Spain, quality control criteria
or RT have been established by law (Royal Decree 1566/1998,
uly 17). These criteria deﬁne and regulate the stages in the
adiotherapy process, as follows: initial diagnosis and patient
valuation, therapeutic decision, tumour localization, irradia-
ion treatment plan, treatment simulation, treatment delivery
nd quality control, and ﬁnal assessment and follow up. Fig. 1
hows the process schematically.1
Once the therapeutic decision has been made and the
atient has been deemed suitable for radiotherapy, the next
tep is to locate the target volume to be irradiated. In
ost developed countries (including ours), localization is per-
ormed via three-dimensional (3D) computed tomography
CT). At present, irradiation treatment planning is based on the
lectron densities measured by CT imaging; for this reason,
here is currently no substitute for CT-based planning. Once
he CT images have been acquired—under speciﬁc conditions
hat can be reproduced in future treatment sessions—the radi-
tion oncologist uses the data to delineate the gross tumour
olume (GTV), also called the macroscopic tumour volume.2
he GTV is the demonstrable extension and localization of
he malignant growth. Three types of GTV are possible: pri-
ary GTV (primary tumour), nodular GTV (metastatic lymph
odes), and metastatic GTV (distant metastasis). Contour-
ng of the GTV is based on data obtained from imaging (CT,
agnetic resonance image  [MRI], etc.), clinical examination,
nd tumour stage. According to the International Commis-
ion on Radiation Units and Measurements (ICRU) Report
o. 83,1 tumour staging should be based on the TNM/AJCC
r UICC staging systems and the ICD-O (International Code
or Disease in Oncology by the World Health Organization).
CRU 83 also recommends that the imaging technique(s) used
or diagnosis (e.g., CT, MRI  T2, FDG-PET, F-MISO-PET, etc.) be
ecorded, in addition to the exact point in time during treat-
ent (e.g., at diagnosis, at 45 Gy, etc.) at which delineation was
erformed.
Once the GTV has been contoured, a margin must be added
o the GTV volume to account for the likely presence of sub-
linical disease, which must also be irradiated. This volume
GTV + margin) is called the clinical target volume (CTV). An
dditional margin, called the internal margin (IM), must then
e added to the CTV. The IM is necessary to account for vari-
tions in the position, size, and shape of the tumour thattherapy 1 7 ( 2 0 1 2 ) 298–318 299
inevitably occur during and between treatment sessions. An
additional margin, known as the set-up margin (SM), must be
added to compensate for imprecision and errors in reprodu-
cing patient positioning and in aligning the therapeutic beams
during acquisition of images for planning purposes and over
the course of treatment. The combination of all these margins
(CTV + IM + SM) results in the planning target volume (PTV), a
geometric concept used for treatment planning. The PTV will
then be used to select the size and appropriate conﬁguration of
the beams to assure that the prescribed dose is actually deliv-
ered to the CTV. Finally, we need to delineate the organs at
risk (OAR), which also requires an additional margin to deﬁne
the planning risk volume (PRV) of the OARs. The purpose of
the PRV is to predict possible complications in healthy tis-
sue. Once the PTV has been designed and the dose prescribed,
the radiation oncologist will then establish dose restrictions
to the PRV. Once this has been done, the medical physicist will
design an irradiation plan that fulﬁls all these conditions and
will send the plan to the radiation oncologist for approval. It
is the responsibility of the radiation oncologist to assure that
the treatment is applied and veriﬁed correctly.
Modern planning and treatment delivery systems are capa-
ble of producing irradiation ﬁelds that deliver the prescribed
dose to the tumour volume with an extraordinary degree of
precision.3 Such techniques—known as conformal RT—utilize
medical images (generally, CT-based images) to develop the RT
treatment plan. Conformal RT also relies on advanced com-
puting tools to perform the complex dosimetric calculations
and to implement strict geometric and dosimetric control pro-
cedures in order to minimize errors.
1.2. The  value  of  PET-CT  in  radiotherapy
Positron emission tomography (PET) with
18F-ﬂuorodeoxyglucose (FDG) plays a very important role
in the diagnosis and staging of malignant lesions, particularly
when hybrid PET-CT imaging studies are used.4 The fusion
of metabolic and structural imaging studies has dramatically
improved the diagnostic precision of PET in oncology.5
Although FDG-PET was not originally designed for planning
radiation therapy, evidence to date indicates that planning
is one of the most promising indications for this imag-
ing modality.6 According to the International Atomic Energy
Association (IAEA), RT planning requires the use of precise
diagnostic methods to assess disease spread, and PET-CT is
one of the most accurate methods currently available. For this
reason, PET-CT is of great use in planning RT, particularly for
tumour locations in which it has already proven its value.7 The
main beneﬁt of PET-CT in RT treatment planning is its ability
to better deﬁne the treatment volume. The use of PET-CT in RT
planning has many  potential beneﬁts: it facilitates contouring,
reduces inter-observer variability in geometric planning, and,
most importantly, can improve the therapeutic efﬁcacy. Simi-
larly, it may also have an impact on the treatment indication
(i.e., curative or palliative). Although the value of PET-CT for
RT planning is still being investigated, it seems highly proba-
ble that this new technology will have a large, positive impact
on treatment planning in the very near future and it may even-
tually replace current CT-based methods.8
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Fig. 1 – Schematic diagram of the radiotherapy process.
Reprinted from ICRU Report 83: Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy
(IMRT). Volume 10, Issue 1, April 2010 by permission of Oxford University Press.1.3.  The  need  for  a  multidisciplinary  group  and  some
general  recommendations
FDG-PET-CT imaging for RT planning is one of the most
complex diagnostic imaging examinations currently avail-
able. Before this imaging modality can be used in therapeutic
applications, we  must ﬁrst fully understand its limitations
and develop standardize protocols for implementation. Impor-
tantly, if we  fail to standardized procedures, it is likely that
results will be unsatisfactory. Although FDG-PET-CT may one
day become standard clinical practice, we  must ﬁrst evaluate
the relevant technical aspects of this technique in RT planning.
The purpose of the present document is to review the technicalfacets of the procedure and to provide recommendations for
clinical use.
In the image  acquisition process of PET-CT for RT planning,
radiation oncologists and nuclear medicine physicians need to
work together in close collaboration. This partnership is cru-
cial due to the enormous organizational effort required and to
assure correct interpretation of the imaging studies. Medical
physicists also play an essential role due to their involvement
in standardizing the process and in quality control. For all
these reasons, multidisciplinary collaboration between radi-
ation oncologists, medical physicists, and nuclear medicine
physicians is absolutely essential if PET-CT imaging is to fulﬁl
its potential for RT planning.
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Recommendations on the use of PET-CT in RT planning
ave been published previously, including those described
y the European Society of Radiation Oncology (ESTRO) and
uropean Association of Nuclear Medicine (EANM) in a spe-
ial issue published in the journal Radiotherapy & Oncology in
010.9 The ESTRO-EANM special issue contains much valuable
nformation and we  highly recommend it to our readers.
The present document provides technical recommenda-
ions for carrying out RT planning based on 18F-FDG PET-CT
n adults. This document is the result of a consensus agree-
ent developed by a working group comprised by members of
he Spanish Society of Radiation Oncology (SEOR), the Spanish
ociety of Nuclear Medicine and Molecular Imaging (SEMNiM),
nd the Spanish Society of Medical Physics (SEFM). The ulti-
ate aim of this working group is to combine our efforts
o obtain the maximum beneﬁt from combined metabolic
nd morphological imaging in the ﬁeld of radiation oncology.
he recommendations described here can be used by cancer
reatment centres that are considering implementing PET-CT
maging in RT treatment planning. An important aim of this
onsensus document is to standardize the process in order to
acilitate comparison of results between different centres.
.  Required  equipment
he CT simulator is the tool commonly used to acquire images
or RT planning, in a process known as CT simulation (or vir-
ual simulation). It is called simulation because images are
cquired with the patient in a simulated treatment position
hat mimics the position that will eventually be used to deliv-
ry radiation therapy. A CT simulator includes:
 a CT with a specially adapted table (a ﬁrm ﬂat tabletop) that
mimics treatment conditions,
an alignment-marking system that uses external lasers,
 a high-capacity workstation for image  manipulation,
 a computer software package to run the virtual simulation.
In order to use FDG-PET-CT in RT planning, the PET-CT
canner must ﬁrst be converted into a PET-CT simulator. This
ransformation requires the following elements:
 Flat table top made of carbon ﬁbre with indentations in the
edges for indexing the immobilization devices. This couch
top should be identical to the one used in the treatment
unit.
A system of external lasers to align the patient and to indi-
cate where the reference marks should be placed on the
patient’s body. The laser system, generally a group of three
beams—two lateral beams for the coronal plane and a beam
located on the ceiling to indicate the sagittal plane—can
either be ﬁxed or mobile. Likewise, the movements of the
lasers can either be manually or automatically programmed
via connection to the virtual simulator console.
 The virtual simulation console, generally located in the
Radiation Oncology Department, requires special tools to
visualize the metabolic images that are co-registered with
CT-based images, as well as tools for semi-automatic seg-
mentation of the metabolic images.therapy 1 7 ( 2 0 1 2 ) 298–318 301
2.1. Gantry  aperture  of  the  PET-CT
At present, most PET-CT simulators in current use have one
key drawback that impedes their ability to precisely repro-
duce conditions in the treatment unit (i.e., linear accelerator):
the distance between the scanner and the body surface. The
gantry aperture of most PET-CT simulators is only 70 cm,
notably less than the ≥85 cm in CT simulators. Recently, how-
ever, new hybrid devices have been introduced to the market
with extra-large apertures of 85 cm.  As more  centres purchase
these devices, this issue will no longer be pertinent.
A larger gantry aperture facilitates patient positioning
under treatment conditions. In addition, a wide scan ﬁeld of
view (SFOV) assures that the entire delineated volume is con-
tained within the limits of the image,  an essential condition
for the use of axial images in RT planning. Conventional scan-
ners (gantry aperture = 70 cm)  provide a maximum SFOV of
48–50 cm and this can be problematic, particularly in contour-
ing tumours in large patients, as the small CT FOV causes some
CT projection views to be truncated, and thus not completely
visualized. The extended FOV, or extrapolated data function,
permits image  reconstruction by widening the FOV. However,
it is important to keep in mind that objects located in that
part of the extrapolated image  may be geometrically distorted
and thus the Hounsﬁeld units may be imprecise—and either of
these factors could lead to errors in dosimetric calculations.10
For this reason, great caution must be taken when using
extrapolated images in RT planning. An alternative would be
to obtain a new series of CT images with a wider FOV and
then co-register these with PET-CT images in the treatment
planning system (TPS).
3.  Interdepartamental  organization
Given that the PET-CT procedures for RT planning require the
participation of multiple departments, coordination and col-
laboration are essential. This multidisciplinary focus requires
that all specialists fully understand the critical aspects of the
whole process—even those aspects that are theoretically the
responsibility of other disciplines—in order to correctly apply
PET-CT for RT planning.
The ﬁrst step is to select the tumour locations that are
considered suitable for PET-CT planning. It is important to
deﬁne all the steps in the process, starting from the moment
the patient is ﬁrst evaluated by the Department of Radiation
Oncology. Given that metabolic avidity varies by tumour and
localization, it is recommended that all factors related to a par-
ticular tumour localization be evaluated before other locations
are considered.
Once consensus has been reached in terms of the method-
ology, the next step is to verify the availability of all necessary
equipment and material (laser, ﬂat table top and immobi-
lization devices compatible with those used in the Radiation
Oncology Department). It is also important to verify compati-
bility and connectivity between the workstations used in the
nuclear medicine and radiation oncology departments.
PET-CT planning has an added beneﬁt apart from improved
contouring: it offers an ideal opportunity to reassess the origi-
nal tumour staging. Most patients undergo diagnostic CT (with
d rad
(
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intravenous contrast) for staging purposes. However, PET-CT
can detect previously unsuspected distant disease in approx-
imately 20% of the most common cancers; as a result, the
addition of PET-CT often leads to changes in staging. In fact,
this aspect of PET-CT further supports its routine application
in order to optimize patient selection.11 All patients should
undergo a standard PET-CT imaging from the orbitomeatal
line to the upper third of the lower extremities before being
included in the RT planning protocol. It is not necessary to
repeat the planning PET-CT if patients have undergone a prior
diagnostic PET-CT in the previous 4 weeks.
To reduce costs, delays, and irradiation, standard PET-CT
(to scan for distant metastasis) should ideally be performed on
the same day as the planning PET-CT. Once distant metastasis
has been ruled out, the planning PET-CT can be sched-
uled (according to an established protocol) to coordinate the
work of the technologists, operators, and nurses involved in
patient positioning, PET-CT acquisition, and intravenous con-
trast administration.
The PET imaging study should be performed from 3 to 5 h
following administration of 18F-FDG to take advantage of dif-
ferences in uptake between tumour and normal tissues. The
contrast between normal and tumour tissues is at its peak dur-
ing this time period. Said another way, the relative metabolic
activity of 18F-FDG in tumour tissues is at its greatest from 3
to 5 h following administration.12
Planning PET-CTs require at least 30 min  more  than
diagnostic PET-CTs due to patient positioning, use of immobi-
lization devices and masks, and in some cases catheterization,
tattoos, preparation of the contrast injector (in cases in which
the CT images are of diagnostic quality) and acquisition of at
least 2 ﬁelds.
The imaging study will need to be evaluated by a physician
from nuclear medicine or radiation oncology to ensure image
quality. After the pathological lesions have been deﬁned, the
radiation oncologist can then select the areas to be treated. It
is important to record the criteria (i.e., metabolic and/or mor-
phological data from the PET and/or CT) used to select the
therapeutic volume, as it is vital to know what data was used to
include (or exclude) a lesion in the treatment ﬁeld. These crite-
ria should be recorded in accordance with the norms required
by ICRU 83 (described in the Introduction section). This is
important because it allows us to assess, during follow up,
the role of each technique (PET and CT) in selecting the cor-
rect ﬁeld to be treated. Moreover, this allows us to evaluate
the association between the imaging technique and possible
loco-regional recurrence and patient survival.
3.1.  Strategies  for  the  use  of  PET-CT  in  RT  planning
Various strategies exist for the use of PET-CT in planning RT.
These are summarized, from least to most complex, below:
a) PET-CT without intravenous contrast. The patient is
positioned on the ﬂat table top, similar to treatment posi-
tioning, but without immobilization devices. The PET-CT
images are used to complement those obtained in the CT
simulation. Both sets of images need to be co-registered.
This method only requires a small amount of extra time
in the PET-CT room.iotherapy 1 7 ( 2 0 1 2 ) 298–318
b)  PET-CT with intravenous contrast. The patient is pos-
itioned on the ﬂat tabletop in the same position that will be
used for treatment, and immobilized by the same devices
that will be used during treatment (these devices should be
prepared previously in another room). Likewise, the refer-
ence marks for daily repositioning should also be applied.
The PET-CT images can then be transferred to the TPS
for planning. This strategy requires the presence of an RT
technologist in the PET-CT room and some extra time, but
no more  than an additional 30 min  at most.
(c) The entire process—simulation plus preparation of immo-
bilization devices—is performed in the PET-CT room, after
which the images are transferred to the TPS. This strategy
requires the presence of a RT technologist in the PET-CT
room and some extra time, at least 30 min  compared to a
diagnostic PET-CT.
Strategy “a” is the simplest and least burdensome in terms
of the extra time needed. The downside, however, is that the
geometric uncertainties of this approach limit the utility of the
metabolic images; in other words, the images can be used to
localize the macroscopic lesions but not for contouring. Strat-
egy “c”, in contrast, is the most time-consuming and could
disrupt the work of a PET-CT team whose primary objective
is clinical diagnosis. Very few radiation oncology departments
(none in Spain) have a dedicated PET-CT for RT planning and,
realistically, strategy “c” requires a dedicated PET-CT. An addi-
tional drawback is greater exposure of staff to the radiation
emitted by the isotope.
Strategy “b” is moderately demanding in terms of its impact
on the PET-CT workload but it is acceptable for the Nuclear
Medicine Department as long as the number of patients
scanned is not excessive. In addition, the images obtained in
this scan can be directly used for planning radiotherapy treat-
ment. Given that PET-CT scanners are usually located in the
Department of Nuclear Medicine, we believe that this strategy
is the least burdensome on the department without compro-
mising the geometric precision required for planning.
3.2.  Patient  preparation:  the  role  of  radiation  oncology
3.2.1.  Patient  positioning
The precision of radiation therapy depends in large part on
proper patient positioning and on the ability of the team to
accurately re-position the patient on a daily basis throughout
the course of treatment. Positioning will also depend on the
tumour location. Table 1 shows the recommended positions
by tumour localization.
Several factors can impede correct patient positioning,
including (a) physical deterioration caused by the cancer; (b)
presence of comorbidities, and (c) patient pain or discomfort.
For example, dysphagia due to tumour growth in the orophar-
ynx or hypopharynx will cause an accumulation of saliva in
the mouth and oropharynx, thus making it difﬁcult for the
patient to remain supine with the neck extended during the
time needed to acquire the PET images. Similarly, supine posi-
tioning is not possible in patients with respiratory or cardiac
comorbidity due to intolerable dyspnoea. Pain can also limit
the patient’s ability to remain in the proper position. Never-
theless, undesired movement  due to pain can be limited or
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Table 1 – Position of patient according to tumour location.
Tumour location Trunk Neck Extremities
Head and neck Supine Extension Arms along the length of the body; caudal retraction of the shoulders
Lung Supine Neutral Arms ﬂexed above the head
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Pelvis-rectum Prone/supine Flexion 
Pelvis-cervix Supine Neutral 
revented by prescribing more  analgesics to control pain dur-
ng simulation.
.2.2.  Patient  alignment
hatever the patient position, his or her longitudinal axis
hould be parallel to the longitudinal axis of the PET-CT table,
ith no lateral rotation around the axial plane. To avoid axial
otation and to align the patient properly, the room should
e equipped with one sagittal and two lateral laser beams
one on each side of the room), and all three beams should
e aligned with the scanner axis.10 The sagittal laser projects
 narrow beam (approximately 1 mm in diameter) in the form
f a fan projected onto the skin of the patient in a line that
hould coincide with centre of the patient’s body through the
nterior side of the head, thorax and abdomen. The lateral
asers project two narrow orthogonal beams onto the patient’s
kin to form two perpendicular lines that deﬁne the axial and
oronal planes. The points where these laser beams intersect
re called triangulation points. The radiotherapy technolo-
ist should place the triangulation points in the anatomical
rea of interest for treatment, and should either tattoo the
atient’s skin at the precise location of these points or mark
he immobilization devices (e.g., thermoplastic masks) if the
riangulation points happen to be coincide with the position of
he immobilization device. For alignment reproducibility, the
kin (or immobilization device) should be tattooed (marked)
t an additional point on the sagittal plane.
.2.3.  Patient  immobilization
n a perfect world, the object scanned for RT planning would
e solid, rigid (i.e., non-deformable), and immobile. Unfor-
unately, the human body is none of these: it is deformable
both externally and internally), and mobile (both voluntarily
nd involuntarily). For this reason, a variety of immobiliza-
ion devices are used to reduce both voluntary and involuntary
ovements during image  acquisition and treatment delivery.
t is highly recommended that these devices be attached to
he ﬂat table top and also that they be indexed (referenced to
 ﬁxed position on the table) to assure precise reproducibil-
ty of positioning during planning and treatment. The use of
mmobilization devices during image  acquisition has proven
seful in reducing movement  artefacts, but these devices must
e indexed and attached to the table to prevent lateral, longi-
udinal, or rotational movements.
.2.3.1.  Indexed  ﬂat  table  top.  The table tops placed over the
T treatment tables are ﬂat (to facilitate repositioning), narrow
to allow the gantry to turn around the couch), and constructed
f rigid, low-density materials (to prevent buckling under the
eight of the patient). Generally they are made of carbon ﬁbre,
n extremely strong yet low-density material.rms ﬂexed above the head
rms in front of the head
rms crossed over the chest
3.2.3.2.  Immobilization  devices.  The main aim of immobi-
lization devices is to avoid involuntary patient movement
during treatment. However, they are also useful in PET-CT
image acquisition since patient movement  between the trans-
mission (CT) and emission (PET) scans will cause errors in
attenuation correction, thereby creating artefacts.13 As men-
tioned previously, the devices should be attached and indexed
to the PET-CT table to avoid movements and should also be
small enough to prevent collisions with the gantry and to avoid
producing artefacts.
3.2.3.3.  Monitoring  involuntary  movements.  It is important to
keep in mind that patients with head & neck or lung tumours
tend to cough frequently and may have deglutition difﬁculties,
both of which increase the likelihood of involuntarily move-
ments during the PET-CT scan. In these cases, the patients
should be carefully monitored to prevent artefacts of move-
ment, or even interruption of the imaging study. For similar
reasons, all individualized immobilization devices should be
prepared beforehand (ideally in an adjacent room) to avoid
prolonging the time spent in the PET-CT.
3.3. Patient  preparation:  the  role  of  the  nuclear
medicine  department
The preparation and administration of the FDG dose, and
image  acquisition should follow the procedures set forth by
the EANM and SEMNiM, given here as follows.14
3.3.1.  Before  the  appointment
- Recommendations by the Department of Radiation Oncol-
ogy should be followed regarding pre-study preparation
(e.g., laxatives for patients with rectal cancer, thermoplastic
masks for patients with head & neck cancer, etc.).
- A brief questionnaire should be given to the patient before
the PET-CT appointment in order rule out possible con-
traindications.
- The possibility of pregnancy should be evaluated in patients
of child-bearing age. In case of doubt, the patient should
be asked to have a pregnancy test and to bring the results
on the day of the PET-CT appointment. For women who
are breast-feeding, feeding should be interrupted for 24 h
following FDG administration.
- Patients should fast for 4–6 h prior to the appointment. This
restriction includes ingestion of candy, gum, and sugary
drinks. It is highly recommended that patients drink water
during this period.
- No physical exercise is permitted in the 24 h period before
the test.
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- Patients should avoid driving a car and other stressful activ-
ities on the day of the appointment. It is recommended that
the patient be accompanied by a family member.
- Patients should drink 2–3 glasses of water and take their
usual medications on the day of the appointment.
- Diabetic patients: patients with diabetes should be asked to
provide details about their treatment, type of diabetes, and
typical blood glucose levels. The patient should be told to
fast prior to the appointment, which should be scheduled
early in the morning.
- In cases in which a CT with intravenous contrast is required,
the usual recommendations should be followed after veri-
fying that the patient has no contraindications for the test
(see below*).
(*) Contraindications
• Absolute contraindications
◦  Known or suspected allergy to iodine contrasts.
◦ Hypothyroidism. Patients with thyroid disease and risk
of developing thyrotoxicosis should be evaluated by an
endocrinologist before and after administration of iodine
contrast:
• Relative contraindications
◦ Renal insufﬁciency. Intravenous contrast can be given
as long as the patient is adequately hydrated and the
contrast dose is reduced. Administration of nephro-
toxic drugs, dopamine, mannitol and diuretics should be
avoided. There is no need to coordinate with dialysis.
◦ Treatment with the oral antidiabetic drug, metformin (a
biguanide). Either of the following two procedures can be
used:
Procedure A:
• Administration of metformin should be suspended 24 h
before intravenous contrast administration and restarted
no sooner than 48 h after imaging and only after serum
creatinine levels have been checked to assure normal kid-
ney function.
• In patients with suspected renal function impairment
(DM > 60 years with HTA) or altered serum creatinine lev-
els, metformin should be suspended 48 h before the study,
and not restarted until 48 h after (with prior assessment
of serum creatinine to assure absence of renal function
impairment).
• In both of these approaches to Biguanides management,
the Biguanides should be temporarily replaced with an
alternative medication prescribed by an endocrinologist.
Procedure B:
Intravenous contrast should not be administered to
outpatients being treated with Biguanides who have cre-
atinine values greater than 1.3 mg/dl.
3.3.2.  During  outpatient  stay  in  the  nuclear  medicine
department
- The nurse in charge should be notiﬁed immediately upon
the patient’s arrival at the department. The nurse should
then notify the technologist, who will set the time for the
image acquisition and contact the supervising physician.iotherapy 1 7 ( 2 0 1 2 ) 298–318
- Patient data should be veriﬁed before any intervention is
performed.
- The physician or nurse in charge should administer a brief
questionnaire to speciﬁcally review current medications,
fasting status, allergy history, and any contraindications to
muscle relaxants or intravenous contrast agents.
- Should insulin be required, the following guidelines can be
used:
• Blood glucose, 200–250 mg/dl: administer 4 units of rapid-
acting insulin.
• Blood glucose, 250–300 mg/dl: administer 6 units of rapid-
acting insulin.
• Blood glucose > 300 mg/dl: notify the physician in charge.
If an insulin shot is given, FDG administration should be
delayed by at least 2 h because hyperinsulinaemia could lead
to increased glucose uptake in the muscles relative to other
tissues.
- The patient should remain supine on the couch, covered
by a blanket, in semi-darkness without any lighting or audi-
tory stimulation for 45–60 min. The patient should not speak
nor chew gum. However, if the patient needs to urinate, this
should be permitted.
- Examinations of the pelvic area may require insertion of
a catheter to ﬁll the bladder with 200–250 ml  to assure
reproducibility of the adjacent pelvic structures. The same
amount of liquid should be used throughout the planning
process. Catheterization should be performed prior to ﬁnal
positioning and before acquisition of the PET-CT image.
3.3.3.  Administration  technique
- Intravenous injection with syringe protector. Avoid admin-
istering the contrast through catheters and permanent
devices.
- With the patient in a seated position, start an intravenous
cannulation using a three-way stopcock. Prepare a connec-
tion to physiological saline solution.
- Verify cannula permeability by injecting 5–10 ml  of physio-
logical saline solution before and after FDG administration,
making sure to prevent extravasation at all times.
- The physician in charge should be immediately notiﬁed of
any incidents that occur during injection; if relevant, these
incidents should be noted on the data collection sheet. If
extravasation occurs, this should be recorded on the data
collection sheet and the procedure can continue without
interruption.
- A total of 500 cc of physiological saline should be adminis-
tered during the ﬁrst 50 min  of the waiting period.
- In patients with breast or lymph node lesions, the radio-
pharmaceutical should be administered in the contralateral
extremity.- The cannula should be removed and the patient instructed
to urinate 45 min  after administration has been completed.
If intravenous contrast is used, only the 3-way stopcock
need be removed.
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.3.4.  Protocol  for  administering  radiological  contrast
gents  (based  on  recommendations  of  the  Spanish  Society  of
edical  Radiology  [SERAM])15
ral contrast media is preferred when acquiring CT images
or RT planning because it improves visualization of the diges-
ive tract. Intravenous contrast media, on the other hand, can
e used to enhance tumour visibility and to identify vascu-
ar structures. However, contrast media can generate artefacts
n the PET images if CT-based attenuation correction (CTAC)
s performed after administration.16 The problem is relevant if
he radioactivity concentration of the contrast agent surpasses
adiodensity levels of 200 HU.17 Even though the increase in
tandardized uptake values (SUV) in areas with high con-
rast concentrations is signiﬁcant when CTAC is performed,
his increase is not clinically relevant. The use of low-density
eutral oral contrast material (barium sulfate 0.1%) does not
roduce clinically detectable errors in PET studies corrected
or attenuation. Moreover, contrast agents have been used in
lanning PET-CT in various anatomical locations without any
pparent effect on clinical results.18
ral  contrast
 In all cases, water should be used as a negative oral contrast.
 Administration protocol
- Administer 600cc (2–3 glasses) of water orally before
injecting the radioisotope.
- Give 250cc (1 glass) of water to the patient to drink upon
entering the PET-CT examination room
ntravenous  contrast  (SERAM  recommendations).  Particular
ttention should be paid to the permeability of the IV can-
ula used to infuse the contrast agent. The infusion pump
hould also be checked to assure that it is working properly.
ny extravasation or inadequate infusion could invalidate the
rocedure by compromising the quality of the CT images or by
ausing patient movement  due to pain at the insertion point.
 test bolus with saline solution should be administered (all
odern contrast media injectors have this capability).
 Use an iodinated contrast agent (nonionic iomeprol or sim-
ilar) delivered through an injector.
Use the same peripheral cannula for administration of FDG.
 Check the system and prepare the contrast infusion accord-
ing to the protocol established by nursing.
 The contrast dose varies depending on the imaging study to
be performed and the patient’s weight. For adults, the range
is usually between 80 ml  and 120 ml.
 Timing of administration:
◦ The contrast agent should be administered during acqui-
sition of the CT data for attenuation correction.
◦ The delay in image  acquisition will depend on the speciﬁc
tumour localization: normally, 20–30 s for head & neck
tumours and 60 s for others, although this protocol can
vary depending on preferences.therapy 1 7 ( 2 0 1 2 ) 298–318 305
4.  Image  acquisition
4.1. Time,  ﬁeld  of  study,  pre-positioning,  and
preparation  for  image  acquisition19,20
The interval between FDG injection and image  acquisition (i.e.,
the uptake period) is perhaps the most critical parameter of
the process. In diagnostic PET-CT, a whole body scan is usually
performed at 60 min  post-FDG administration. In contrast, for
RT planning, the scan should be performed at least 3 h after
FDG injection because tumour detection sensitivity increases
over time. FDG concentration in cancerous tissue will vary by
tissue type, but concentration levels increase in all types for
at least 90 min  after injection. Unfortunately, it is not possi-
ble to compare the results of most case series that have been
published to date due wide variations among these studies
in the time at which SUV data were measured. To avoid this
problem in the future, we recommend that variation in uptake
time from patient to patient be limited to less than 10 min. In
clinical practice, this requires careful planning between FDG
administration and the start of imaging. SUV is a stable and
highly reproducible parameter, but only when strict protocols
are followed for data acquisition and analysis.
Patients should be instructed to empty their bladder before
the scan to limit radiation to the urinary system. All metallic
objects must be removed whenever possible. A ﬂat table top
similar to the one used for treatment is recommended. The
patient should be carefully placed in the same position for
both simulation and treatment; this alignment process should
be guided by laser beams and the skin markings that deﬁne the
treatment area.21 The same immobilization devices should
be used for both simulation and treatment. If thermoplastic
moulds have been created, these same moulds should be used
for positioning.
To check for distant metastasis, we recommend scanning
from the skull base to the proximal third of the thigh. For
tumours with a high afﬁnity for the scalp, skull or brain, the
head should be included in the ﬁeld. For optimal evaluation
of the head and neck region, the arms should be extended
along the side of the body. Similarly, for the thorax-abdomen-
pelvis, patients should be positioned with their arms elevated
above the head to avoid beam-hardening artefacts and arte-
facts caused by truncation of the FOV on the CT image.  Pelvic
imaging should be performed with the patient in prone posi-
tion. Patients with rectal cancer should have a full bladder.
Generally, image  acquisition is performed by moving the
table top through the detection ﬁeld until the relevant areas
have been scanned. Depending on the model of the tomo-
graphic scanner, the axial detection ﬁeld measures from 15
to 25 cm,  thus requiring from 5 to 10 table top movements to
examine the entire body. The mean duration for each table top
position can range from 2 to 5 min.
4.2.  CT  protocol22CT is a valuable tool with many  possible uses: attenuation
correction, localization of hypermetabolic lesions, volume
contouring in RT planning, and, of course, for diagnostic
purposes. When CT is used for attenuation correction, the
d rad306  reports of practical oncology an
milliampere-second setting is low (40–50 mAs) to reduce the
radiation dose to the patient. In contrast, a much higher
setting (>120 mAs) is needed to acquire images of sufﬁcient
quality to enable contouring without the need for contrast
media.
Diagnostic CT imaging is performed with intravenous con-
trast and tube current modulation. The use of intraluminal
contrast provides adequate visualization of the gastrointesti-
nal tract and the contrast agent can be positive (diluted
barium) or negative (water). Because high barium concentra-
tions can produce an attenuation artefact with a signiﬁcant
overestimation of 18F-FDG concentration, the barium must be
diluted to assure image  quality.
• Acquisition of the topogram.  The ﬁrst step in image  acquisi-
tion in a PET-CT scanner is to acquire a topogram (overview
scan). This image  is obtained with the x-ray tube locked
in a ﬁxed position—typically a frontal position, although
other positions are possible. The topogram is obtained with
the table top in continuous movement  in order to acquire
an anatomical image  that reveals the distinct structures; it
is this image  that the operator will use to deﬁne the axial
extension of the PET-CT image.  Once the limits of the imag-
ing study have been determined, the acquisition ﬁelds of
both (PET and CT) should be adjusted such that the acqui-
sition of the CT (with continuous movement  of the table
top) coincides in extension with that of the PET scan (with
discrete movements of the table top). In some PET-CT scan-
ners, the FOV of the CT and PET differ (e.g., 50 cm for CT and
60 cm for PET), leading to differences in the images. In this
case, it is important to verify that the image  with the smaller
FOV (normally the CT) includes all relevant body regions. If
left uncorrected (i.e., by failing to reposition the patient),
these differences in FOV can cause truncation artefacts on
the reconstructed images.
• CT acquisition. This is performed in the standard way,
with a speciﬁc breathing protocol during image  acquisition
(smooth and superﬁcial breathing) designed to help make
the CT and PET images coincide more  precisely. Various
parameters can affect the time needed to acquire the CT
image: the size of the anatomical region of interest; the
number of slices of the CT scanner; the tube rotation speed;
and the speed at which the table top is moved. Whole body
imaging usually takes less than 1 min. Artefacts produced
by respiratory movements are especially relevant in lesions
located at the base of the lungs and in the liver dome. For
this reason, depending on the resources available, an addi-
tional inspiratory chest CT can be performed to evaluate
lung nodules, or for 4D PET-CT.
4.3.  Protocol  for  PET  emission  scan
Once the CT study has been completed, the table top can be
moved in order to position the patient in the FOV for the
PET tomography. The PET-CT operator will decide when to
begin the examination as well as the direction of the table top.
When it is important to limit the artefact produced by radio-
pharmaceutical accumulation in the bladder, a caudocranial
orientation is used. PET imaging is performed by acquiring theiotherapy 1 7 ( 2 0 1 2 ) 298–318
sinograms in the various table top positions that comprise the
ﬁeld examined in the CT. The total duration of the PET scan
depends on the number of table top positions and the time
allotted for the scan at each position. Depending on the tomo-
graphic model (2D or 3D), the total duration ranges from 6 to
35 min. Late PET imaging-performed between 90 and 180 min
following FDG injection-improves the lesion-to-background
ratio, thus facilitating image  interpretation.
4.4. Dosimetry
In FDG PET-CT studies, the effective dose of radiation deliv-
ered to the patient is the sum of the radiopharmaceutical dose
(approximately 10 mCi  of 18F-FDG [6–7 mSv]) and the CT dose
(2–4 mSv), with a typical total dose of approximately 10 mSv.23
The CT dose is highly variable depending on the protocol and
systems used, and dosimetric optimization can reduce the
dose. The effective dose ranges from 2 to 80 mSv  but this must
be calculated for each system and protocol.
For 18F-FDG, the effective doses per unit of activity admin-
istered (mSv/MBq) are as follows24:
Radiopharmaceutical Adult 15
years
10
years
5
years
1 year
18F-FDG 0.0183 0.0233 0.0356 0.0534 0.0927
5.  Interpretation  criteria  for  metabolic
images
Interpretative criteria for FDG-PET for diagnosis of tumours
have been widely described in the literature.14 In this sec-
tion, our aim is primarily to provide the reader with a reﬂexive
(rather than objective) approach to interpretative criteria. We
include these tentative criteria to help develop consensus rec-
ommendations for PET planning in radiotherapy. By no means
are these criteria to be considered deﬁnitive.
The sensitivity and speciﬁcity of PET vary by tumour type
and each case must be considered on its own. This, of course,
has implications for RT planning. In general, if the aim is
to treat the whole tumour, it is best to use interpretative
criteria that have a high sensitivity (assuming a low speci-
ﬁcity), with the understanding that non-cancerous tissue (i.e.,
healthy tissue) will likely be included in the radiotherapy ﬁeld.
Such an approach is appropriate for treatments with curative
intent. For example, if anomalous tracer deposits are found in
regional or distant lymph nodes, these should be considered
positive and included in the treatment volume. In contrast,
if our main objective is to reduce morbidity by minimizing
radiation to healthy tissues, then the interpretative criteria
should have a greater speciﬁcity—even though this implies an
increased risk of relapse. In such cases, all relevant diagnos-
tic procedures (including biopsy) should be performed to rule
out or conﬁrm the positive PET ﬁndings before the therapeutic
approach is planned.
The sensitivity and speciﬁcity of FDG-PET is slightly bet-
ter than conventional morphological imaging exams for nodal
staging in head & neck tumours, although the diagnostic dif-
ferences between functional and morphological imaging are
not statistically signiﬁcant25 in this case. Even so, PET imaging
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s valuable as a complementary technique with a potential
ole in RT planning. The potential advantages of FDG-PET are
s follows: a decrease in interobserver variability in contour-
ng the GTV; a smaller GTV in most cases; identiﬁcation of
ctive disease that remain undetected by other techniques
CT and/or MRI); and the ability to identify areas of the GTV
hat might require an additional dose of radiotherapy.26 Other,
ore  speciﬁc beneﬁts of FDG-PET include GTV contouring via
utomated segmentation methods, and deﬁnition of the iso-
ose distribution to the primary tumour. Preliminary data also
uggest that PET may have a promising role in adaptive treat-
ents and in patient follow-up.
The sensitivity of FDG-PET is superior to CT for stag-
ng non-small cell lung carcinoma (NSCLC), with the main
dvantage being that FDG-PET has a high negative predictive
alue (>90%) in the detection of mediastinal node metastasis
n patients without previous chemotherapy.27 Approximately
0% of positive ﬁndings for mediastinal nodal involvement
re false positives. As a consequence, if a true positive would
mply a change in the therapeutic approach or intention,
hen any suspected pathological focus detected by FDG-PET
hould be conﬁrmed by mediastinoscopy or by ultrasound-
uided endoscopy with ﬁne-needle biopsy. When FDG-PET is
sed for planning radiotherapy, the treatment volumes are
ften smaller—mediastinal volumes may be smaller in 80%
f patients. This has an important beneﬁt: the therapeutic
ose can be increased with less toxicity to surrounding organs.
DG-PET has also been shown to be capable of detecting
istant metastasis in more  than 30% of stage III patients pre-
iously staged as M0  by conventional techniques.27 In such
atients, this ﬁnding implies a change in the surgical approach
nd perhaps even in the treatment intention.
PET is widely used for diagnostic staging, early assessment
f response to therapy, restaging, and diagnosis of recurrence
n many  types of gastrointestinal tumours. However, due to
ts low sensitivity in detecting nodal disease in esophageal
ancer, radiotherapy to these areas cannot be omitted even
ith a negative ﬁnding on PET. On the other hand, PET has
 higher speciﬁcity in ruling out nodal disease,28 so that any
eposits in the supraclavicular or celiac trunk nodes can be
onsidered positive and should be included in the GTV.
In conclusion, interpretation of the PET to select RT vol-
mes and ﬁelds depends on the intrinsic diagnostic values for
ach situation and the therapeutic intention.
.1.  Interpretation
he ﬁrst step is to visually assess the image.  The physiological
istribution of FDG and any variation from normal should be
stimated.29 All increases in FDG uptake relative to surround-
ng tissue and/or equivalent regions that do not correspond
ith physiological uptake should be considered malignant.
Optionally, a semiquantitative study can be performed to
etermine the SUV indices for each observed lesion. The SUV
ndex is the uptake of the radiopharmaceutical measured in
Bq/ml in the region of interest (ROI) and the injected dosein MBq) divided by the body weight of the patient in grams.
For most tumours, the reported SUV threshold separating
enign from malignant tumours is 2.5–3 MBq/ml. It is impor-
ant to note that these ﬁnding come from PET studies in whichtherapy 1 7 ( 2 0 1 2 ) 298–318 307
attenuation mapping was performed with isotopic sources
(68Ge or 137Cs), not CTAC; when CTAC is performed, uptake is
signiﬁcantly greater, a fact that needs to be considered when
interpreting SUV.
The value of the SUV index depends primarily on biological
factors and tumour histology.30 In addition, SUV assessment
must include numerous factors that affect its interpretation,
such as when SUV levels were measured, endogenous glucose
levels, the partial volume effect (PVE), and the size and location
of the ROI.31
FDG distribution is not homogeneous, with uptake varying
by tissue type (e.g., uptake is higher in muscle vs. fat tissue).
For this reason, the formula used to calculate SUV has been
modiﬁed to account for these variations and other factors such
as the patient’s constitution: the modiﬁed formula allows us
to correct for body surface area and muscle mass.
Despite the multitude of factors affecting SUV, their impact
is less important when the purpose of SUV is to evaluate and
monitor the therapeutic response. This is because therapeutic
response can be measured by assessing the relative change
from the initial SUV value. Nevertheless, to ensure consis-
tency from study to study, it is imperative that we  standardize
SUV measurements as much as possible (e.g., the same scan-
ner and radiopharmaceutical dose should be used to monitor
ongoing changes in the disease). Criteria to standardize SUV
measurement have been described in several recently pub-
lished consensus documents.32
Physiological uptake of 18F-FDG is observed in viable tis-
sues, including the brain, myocardium, breast, liver, spleen,
stomach, intestines, kidneys, bladder, muscle, lymphoid tis-
sue, bone marrow, salivary glands, thymus gland, uterus,
ovaries, testicles, and brown fat. For whole body studies, the
sensitivity of 18F-FDG to detect cerebral brain metastases is
low, mostly due to the high physiological uptake of grey mat-
ter.
High uptake of 18F-FDG is observed not only in neoplas-
tic processes, but also in granulation tissue (i.e., wounds),
infections, and other inﬂammatory processes. If we wish to
interpret PET-CT images correctly, we must take these factors
into consideration. In order to differentiate between benign
and malignant lesions, we must consider 18F-FDG uptake pat-
terns and the speciﬁc ﬁndings of the CT in the larger context
of the patient’s medical history, physical exam, and other
imaging techniques. In evaluating response to therapy, it is
especially necessary to perform a semi-quantitative estima-
tion (SUV).
5.2.  What  is  the  SUV?  Deﬁnition
FDG concentration in a cancer patient can be assessed in
many  ways, some of which are relatively simple and others
highly complex. The simplest method is a qualitative evalu-
ation that requiring only a good quality image.  In contrast,
certain quantitative methods-such as the space-time quan-
titative description-require kinetic methods, dynamic studies
and complex data analyses. Somewhere between the simplest
and most complex methods lies the SUV, which is a reasonable
compromise.
SUV stands for Standardized Uptake Value, a measure of
the radioactivity concentration (Bq/ml) in a speciﬁc area. The
d rad308  reports of practical oncology an
formula to calculate the SUV is as follows:
SUVbody weight (kg/ml)
= decay corrected activity in region of interest (Bq/ml)
injected dose (bq)/body weight (kg)
Ideally, this formula would yield values of sufﬁcient
magnitude to function as reference values, making them inde-
pendent of the particular study and patient; in such a scenario,
a speciﬁc uptake value would be considered pathological if
above a speciﬁc level. However, the reality is that SUV is
inﬂuenced by multiple factors and is highly variable. The fac-
tors that have the largest inﬂuence on SUV are shown in
Table 2.33
SUV is not a real physical value, but rather a rela-
tive value that depends on factors such as the size of the
Voxel, patient movement, characteristics of the PET scan-
ner, the technique used for image  reconstruction, and the
number of iterations in the reconstruction. While some fac-
tors are not under our control, others are, and to reduce
variability in these factors we need to standardize mea-
surements as much as possible.34 Guidelines are needed
to standardize quantiﬁcation in future FDG-PET studies;
otherwise, comparison between hospitals will not be possi-
ble.
6. Segmentation  methods  for  metabolic
images
As discussed in the introduction, the radiation treatment plan
must be based on the most precise diagnostic methods avail-
able. In 2006, an IAEA expert panel reviewed the use of PET-CT
in RT planning and one of their main conclusions was the
need to accurately assess disease spread before planning and
delivering radiotherapy.7 In many  types of tumours, PET-CT
has proven to have superior speciﬁcity and sensitivity com-
pared to CT alone, mainly as a consequence of the extra
information provided by metabolic data. These ﬁndings have
stimulated interest in PET-CT for both diagnosis and treatment
planning.
Newer, more  advanced technologies such as intensity-
modulated RT (IMRT) and image-guided RT (IGRT) allow highly
precise delivery of conformal doses to the tumour with steep
dose gradients. At the same time, however, such steep gra-
dients make precise contouring of the target volume more
important than ever before.
The images used in radiotherapy planning allow us to
deﬁne the GTV for the primary tumour and any nodal dis-
ease. Classically, CT has been the tool of choice to obtain the
morphological tumour image  and its main advantage is that it
allows contouring directly over the tumour image.  In contrast,
an important disadvantage of CT-based images is that they are
less useful in deﬁning the CTV. Fortunately, the emergence
of PET imaging and its ability to provide functional informa-
tion is yielding new information about GTV subvolumes, and
these data can be included when contouring volumes. Some
authors now even use the terms “metabolic” or “biological”35
volumes based on metabolic data from the PET scan. Despiteiotherapy 1 7 ( 2 0 1 2 ) 298–318
the appeal of such terms, the ICRU 83 report advises against
using these terms, suggesting instead that we  specify the type
of study performed (GTV FDG-PET, GTV PET-FMISO, etc.) and
when the image  was obtained (0 Gy, 45 Gy, etc.). Other spe-
cialists have suggested that PET can directly deﬁne the CTV.36
It would seem, for the moment anyhow, that the low resolu-
tion (∼5 mm)  of current scanners does not allow us to make
such bold claims. Nevertheless, other authors are even more
optimistic, suggesting that functional and biological imaging
will eventually allow us to move from a “clinical” to a “real”
volume.37
Radiation oncologists are accustomed to using the sharp,
clear images provided by CT to delineate treatment volumes.
The images produce by PET scans are, in contrast, much
“fuzzier” and, as a result, the intra- and inter-observer vari-
ability of PET-contoured volumes are potentially much greater
than volumes delineated on conventional CT images. More-
over, selection of the “window” in which treatment volumes
are contoured is even more  important.
Segmentation refers to the act of segmenting volumes (cut-
ting or splitting into segments). When using a PET image  to
contour our GTV, we must choose the area (segment) that
lies within our GTV and which, therefore, we  interpret as the
tumour target.
When an image  is acquired and used for treatment plan-
ning, we move from the “tumour reality” to the “tumour
image” and from this image  we must then infer the “tumour
reality”. If we overestimate the real tumour volume, the result
will be an unnecessary increase in the size of the treatment
volume, which could lead to increased toxicity to the adjacent
OARs. Underestimation, in contrast, could result in a danger-
ous loss of local tumour control.
Various segmentation methods have been used to plan RT
treatments with PET-based images. The “gold standard” for
validating these methods has generally been the pathologi-
cal specimen. Nevertheless, this validation method may be
less than ideal given the likelihood that “ex vivo” analysis of
the sample (particularly the specimen volume) may not cor-
respond to its “in vivo” characteristics (e.g., lung tissue).
The aim of segmentation is to classify the image  in terms
of “tumour or not tumour”. Classiﬁcation is a statistical
technique applied to segmentation and several different clas-
siﬁcation methods, with varying degrees of mathematical
sophistication, have been used to perform segmentation.
Segmentation of PET images is difﬁcult due to the low spa-
tial resolution and high level of “noise” of the images.38 To
overcome these obstacles, many  attempts have been made
to apply mathematical methods to obtain a quantitative
response that is reproducible, observer-independent, and that
reﬂects as realistically as possible the “tumour reality”. How-
ever, to date, researchers have been unable to develop a
reliable method that fulﬁls those characteristics while also
reﬂecting the clinical experience of different specialists and
the particularities of the patient and the disease.
Three methods can be used to evaluate PET images:
qualitative (i.e., visual interpretation); semi-quantitative (i.e.,
based on SUV); and kinetic-quantitative (i.e., a method
that accounts for variation in uptake time). The segmen-
tation methods can be divided into three categories, as
follows:
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Table 2 – Most relevant factors impacting the SUV.
Patient-related Instrumentation-related Operator-related
Not controllable
• Patient size
• Postural ﬂexibility of the patient for
the various treatment positions.
• Capacity of patient to remain
immobile in a given position.
• Patient movement and breathing.
• Levels of blood glucose and insulin.
• Non-uniform uptake within the
tumour (necrotic centre)
• Diffusion in the tissue.
Controllable
• Radiopharmaceutical
•  Isotope emission +
• Dose administered.
•  Residual activity in the needle.
• Uptake time before acquisition of
•  Partial volume effect
• Discrimination in scatter events
• Sensitivity
• Mode of acquisition (2D vs. 3D)
• Method used to correct attenuation (CT
vs. Germanium sources)
• Truncation
• Movement (different time scales, CT vs.
PET)
• Acquisition with respiratory control (4D)
• Availability of corrections for movement
• Artefacts due to CT movement
• Use of contrast agents
• Subtraction of the background
• Reconstruction Algorithm: (Filtered Back
Projection vs. OSEM)
• Reconstruction by time of ﬂight
nizat
• Quality of injection administration
• Acquisition and reconstruction
protocols
• Image acquisition time
• Image interpretation
• Difﬁculty determining the SUV
threshold
• Analytical tools not designed to
measure a change in SUV
• Interobserver variability
• Determination of ROI
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ative threshold overestimates the real volume in tumours
<12.5 mm.  In a letter to the editor,42 Hoffmann et al. pointed
out the limitations of this method. They noted that the
Fig. 2 – Absolute threshold = background + relativeimages
• Acquisition time
• Incorrect synchro
.1. Visual  or  manual  (qualitative)  methods
he ﬁrst segmentation method—visual or manual
egmentation—is the most intuitive. Despite the obvious
ubjectivity of the method, it is no less valid than the others.
s the name implies, visual segmentation is based on a quali-
ative analysis of the images; in expert hands, this qualitative
valuation can be quite useful. Typically, this method relies
n a visual assessment of the PET image  to identify and select
reas of pathological uptake. These areas are then contoured
y CT to take advantage of the greater spatial resolution of
T, which allows for a clear deﬁnition of the tumour borders
unlike PET). However, one criticism of this approach is that
athological metabolic uptake may not coincide with the
oundaries visualized on CT.39
.2.  Threshold  methods  (semi-quantitative)
he subjectivity of the visual method—with its intra- and
nter-observer variability—has prompted a search for auto-
ated segmentation methods to help reduce variability. The
hreshold method is based on a semiquantitative analysis (i.e.,
UV) of the images. To implement this methodology, how-
ver, we  need to identify the multiple factors that can affect
uantiﬁcation of PET images (see Section 5.2 for more  details).
Threshold methods use a speciﬁed uptake level (the thresh-
ld level) as a cut-off to determine whether a tissue area
hould be included in the treatment volume. Some thresh-
ld methods use absolute SUV cut-off values while others use
 percentage of maximum SUV. Studies in phantoms40 have
een performed to determine the relationship between the
eal volume of a lesion and the optimal threshold level that
ccurately depicts that real volume: in low-contrast lesions
low signal-to-background ratio [S/B]), adequate threshold
evels were typically higher. This type of automated segmen-
ation requires an a priori estimate of the size of the lesion
f interest, usually obtained by CT. In tumours larger than
 ml  and S/B > 5, the size of the lesion can be predicted with
 reasonable degree of accuracy when ﬁxed threshold levelsion of watches
ranging from 36% to 44% of the maximum SUV are used. How-
ever, this is not the case in smaller tumours.
To solve this problem, Daisne and Gregoire41 validated a
segmentation method that was independent of the size of the
object of interest. They showed that selection of the proper
activity threshold was actually a function of the S/B ratio, at
least for volumes greater than 2 ml  with a S/B ratio > 1.5. They
validated this method for several reconstruction algorithms.
Davis36 later described a new concept called the “relative
threshold level”. This new threshold level is also a percent-
age of the maximum signal, but with the background signal
previously subtracted (Fig. 2).
The relative threshold level that most accurately repre-
sents the real volume is 41 ± 2.5% (background subtracted
from the signal); however, it should be noted that this rel-threshold (maximum signal – background).
Reprinted from Radiother Oncol 2006;80:43–50 by J.B. Davis,
Assessment of 18F PET signals for target volume deﬁnition,
copyright (year) with permission from Elsevier.
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Fig. 3 – Optimal threshold value depending on the shape.
Reprinted from Medical Physics (King MA,  Long DT, Brill AB.
SPECT volume quantitation: inﬂuence of spatial resolution,
source size and shape, and voxel size. Med  Phys
1991;18:1016–24) with kind permission from Springer
Science and Business Media.
optimal threshold necessary to ﬁnd the true “border” is a func-
tion of the diameter and shape of the tumour, as King et al.43
also pointed out (Fig. 3). As a result, there is no optimal thresh-
old level that can be applied to the myriad sizes and shapes of
tumours.
The optimal threshold depends on the size, shape, and
uptake levels of the lesion (Fig. 4). Fig. 4 shows the real sil-
houette (in black) of a virtual phantom with an irregular
shape (“peaks”), a vertical gradient of the grey value within
background noise. The isocurves are delineated in red. Note
that the isocurve that ﬁts the upper peak well actually
Fig. 4 – Differences in delineating a real object at different
threshold levels.iotherapy 1 7 ( 2 0 1 2 ) 298–318
overestimates the lower peak. The same is true when the
isocurve is optimized to ﬁt the lower peak. In short, even when
various threshold levels (red line) are used, it is not possible to
reliably reproduce the original image  (black).
For an object whose diameter is less than 10 times the res-
olution (given as full width at half maximum; FWHM), there is
a single threshold value that represents the real volume only
if: (1) the object is spherical; (2) uptake is uniform both within
and without the object; and (3) the point-spread function (PSF)
is isotropic and constant throughout the entire FOV. Unfortu-
nately, tumours in the real world do not meet these conditions,
so it will be difﬁcult to ﬁnd an optimal threshold level that
precisely reﬂects the actual tumour.
Bielh et al.44 showed that there is a logarithmic relationship
between the tumour volume and the optimal threshold level,
using CT-contoured lung tumours as a gold standard to ver-
ify the relation. This inverse relation (the smaller the tumour
volume, the larger the threshold needed) was subsequently
proven in phantoms.45,46
In general, for small spheres, a high threshold (>50%) com-
pensates for uptake loss typical of the partial volume effect.
For medium size spheres, the PVE is negligible but the borders
are not as sharp, thus requiring a lower threshold. In large
spheres, the PVE and the fuzziness of the borders are negligi-
ble and the threshold is approximately 50%. Thus, threshold
levels of 35%-45% correspond to radius/FWHM ratios typical
of medium-sized lesions (approximately 4 cm diameter) rep-
resented in conventional PET (with a FWHM of 4–7 mm),  a
fact that supports optimal threshold levels of approximately
40%-precisely the levels recommended by numerous authors.
The proper threshold to reﬂect the correct size of a lesion
depends both on the signal-to-noise ratio as well as the PVE. To
determine this relationship, we  must ﬁrst obtain a calibration
curve in phantoms with spheres of a known size (Fig. 5) and
the same radioactivity.
Prior calibration is essential in order to determine the cor-
rect threshold level that should be applied to a lesion of a given
size once the signal-to-noise ratio of the speciﬁc PET-CT scan-
ner is known. Also, by calibrating the scanner, we  can later
perform comparisons between centres.
Fig. 5 – Partial volume effect.
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.3.  Variational  approaches  (gradient  method)
he aim of these methods is to assess variation in intensity to
dentify the maximum gradient of intensity between tumour
ptake and background uptake. The point or area of maximum
ariation is assumed to represent the lesion borders.
The “gradient” method was ﬁrst described by Geets and
olleagues in 2007.47 Using pathological specimens from head
 neck cancer patients as a gold standard for validation,
his method reduced the size of the false positive volume
ut at the cost of increasing the false negative volume. In
ther words, the gradient method reduced overestimates of
he real volume but increased the risk of missing part of
he tumour. Subsequently, other gradient methods, available
ommercially and validated pathologically in lung tumours,
ave been described.48 One of the main limitations of gradient
ethods is their high sensitivity to background noise.49
.4.  Other  methods
ue to their mathematical complexity, anyone wishing to use
he highly sophisticated methods mentioned below will need
o consult a specialist with real expertise in these techniques.
hese models use complex algorithms to compensate for the
eﬁciencies of the previously described methods. Importantly,
owever, the difference in results between these highly com-
lex methods and the other methods described above is only
 few millimetres. The subpixel precision of some of these
ethods is such that is of little value in current daily clinical
ractice.
Tumour size and heterogeneity have less of an impact on
hese methods, but image  quality needs to be excellent. Two
f the more  common of these methods are learning methods
nd stochastics. Segmentation methods based on a kinetic-
uantitative analysis are still being studied and none are yet
vailable for clinical use.
To conclude this section, we  can state that the most robust
nd best method has yet to be determined. However, to
dentify the best method, we will ﬁrst need to standardize
ur approaches and then compare ﬁndings among different
roups. In general, we advise against the use of ﬁxed thresh-
lds; instead, we  recommend the use of adaptive thresholds
hat take background noise into account. Keep in mind,
owever, that ﬂexible thresholds require precise calibration.tion and fusion processes.
Finally, the extreme complexity of some methods (stochas-
tics, learning methods, etc.) is probably not worth the effort, at
least at present. Frankly, for departments without strong sup-
port from the medical physics department, we  recommend
manual segmentation.38
7.  Physics  and  radioprotection
7.1.  Why  quality  control  is  needed
The addition of functional imaging to radiotherapy planning
requires the inclusion of biological information (in addition
to anatomical information obtained mainly through CT and
MRI) to provide information about the functional and molec-
ular heterogeneity of the target tissues and in some cases, the
adjacent healthy tissues (Fig. 6).
The use of multimodal imaging, particularly functional
imaging, implies a change in the radiotherapy process, as
two new steps (image registration and signal quantiﬁcation)
must be added. The ﬁrst step, image  registration, is performed
to “geographically” determine the biological information so
that a one-to-one correspondence between the anatomical
and functional pixels can be made. The second step, signal
quantiﬁcation, is performed prior to volume delineation to
establish the qualitative (if referring to a speciﬁc molecule)
or quantitative (if referring to signal intensity) signal level
that indicates the existence of a target volume. Performing
these two steps will then allow us to continue with the usual
radiotherapy planning and treatment process. In the present
section we discuss some aspects of these steps. However,
for detailed, step-by-step quality control protocol (frequency,
etc.), we encourage readers to refer to the references cited.
7.2.  Quality  control  of  the  equipment
The objective of quality control of the PET-CT system is to
verify the operational integrity of the detectors and elec-
tronic chain used for image  acquisition in order to maintain
a high-quality image  while minimizing artefacts. To incorpo-
rate PET-CT images for radiotherapy planning, quantiﬁcation
and registration must be precise, which is why quality control
checks need to be performed. The typical CT scanner quality
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Fig. 7 – Dependence of the linear attenuation coefﬁcient on
photon energy. Figure created from data published by
Hubbell and Seltzer57.
control tests used in RT, such as those listed below, should be
performed.50–53
• Veriﬁcation of laser centering system.
• Precision in the table top movements.
• Image  quality.
• Patient dose registration (CT dose index).
• Transfer and manipulation of the image  in the TPS.
In addition to quality control of the CT scanner, we  must
also check the PET. For instance, we must consider plane align-
ment between CT and PET imaging studies, and also new
functions related to registration, fusion, segmentation, and
inﬂuence of the dose calibrator.54,55
In the following section we describe the essential quality
control tests and procedures for SUV-based PET-CT imaging in
radiotherapy treatment planning.54 In a perfect world, each of
these tests would produce a numerical value (an uncertainty
factor) that would permit us to precisely calculate the addi-
tional margin needed to incorporate that uncertainty into our
clinical practice; the resulting margin could then be used to
deﬁne the treatment volumes. These tests still provide use-
ful information, but mostly to establish tolerance ranges that
indicate whether the treatment is acceptable or not. The tests
selected will depend on the degree of precision desired: a qual-
itative evaluation of the diagnosis requires less precision than
a quantitative description of changes in uptake. This decision
will determine the most relevant tests needed for both quality
control procedures and tolerances.
7.2.1. Acquisition  equipment
7.2.1.1.  Mechanical  tests.  In this section we have included
tests designed to assure the integrity of the coordinates sys-
tem, deﬁned by laser alignment and agreement between the
coordinates system, and that of the PET and CT imaging
planes. Most of the latest scanners include tools to performiotherapy 1 7 ( 2 0 1 2 ) 298–318
end-to-end testing to assure that the CT and PET planes coin-
cide.
The main tests should verify the following.
Laser alignment:
•  Alignment between the gantry and room lasers. Both sys-
tems should not only be coincident, but parallel.
• Alignment between the gantry laser and the imaging plane
from the coordinate origin of the imaging study.
• The laser projections and the scanner should be parallel and
orthogonal with respect to the imaging planes.
Table top movement:
•  Orthogonal movement  relative to the image  acquisition
plane.
• Precision and reproducibility of both longitudinal and ver-
tical movements.
• Veriﬁcation of the precision of the table top indexing and
positioning, controlled by the scanner.
• Veriﬁcation of the previous indication under clinical condi-
tions with a weighted table.
A ﬂat, indexable table top should be used together with
the immobilization devices in order to exactly reproduce the
conditions under which both simulation and treatment are
carried out.
PET-CT alignment:
• Multimodality phantoms should be used for end-to-end
testing (CT/MRI/PET-CT). The object of the test is to verify
correct registration of the reconstructed CT and PET images.
To do this, a phantom that allows radioisotope-ﬁlled (“hot-
rod”) inserts inside or outside the phantom should be used
to verify agreement between the PET and CT images under
clinical conditions. Usually, the manufacturer can provide
such a phantom, often composed of 68Ge rods, for use in
calibration and correction of any offset between the PET and
CT planes.
7.2.1.2.  Quality  control  tests  for  the  images.  In general, these
tests are designed to assess and assure the reliability of image
quality.
• Homogeneity and lack of artefacts. Both modalities assure
topographic uniformity. In reconstruction of the PET image,
the CT transmission image  is used to perform attenuation
correction, due to the different distances travelled by the
photons emitted from the interior and surface of the phan-
tom and due to differences in energy spectrum between CT
and PET. Attenuation correction can produce artefacts when
contrast agents are used, or in patients with a prosthesis.56
• Resolution and contrast of CT and PET images. PET resolu-
tion is measured in and outside of the axis and this directly
affects signal quantiﬁcation (see below for a more  in-depth
discussion of this aspect).• Determination of the attenuation coefﬁcients for var-
ious electron densities. Attenuation coefﬁcients are
energy dependent and attenuation also depends on the
material—soft tissue, bone, and iodine (used in most
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contrast agents). To some extent, electron densities depend
on the kilovoltage used (Fig. 7).56
Quantiﬁcation tests of the PET signal:
Sensitivity. 2D and 3D calibration. The purpose is to deter-
mine the rate of coincidence events per unit of radioactivity
concentration. This factor is then used to calculate the
image  pixel value, given in concentration units.
 Quantiﬁcation of the PVE. The partial volume effect is due to
the limited spatial resolution of the detectors. This results in
a signal loss in the tissues of a size that approaches the res-
olution limits of the imaging system. This signal loss can be
quantiﬁed in phantoms through the use of hot-rod inserts of
ig. 9 – Dose rate at 10 cm and 1 m on average for 10
atients injected with approximately 370 MBq  and at
0 min  following injection.tion and fusion processes.
varying sizes under various conditions (dependence on the
tracer concentration, radioactive background, movement,
etc.) by which various curves are obtained under differ-
ent conditions that are applied on segmentation.41,58,59 This
effect can also be affected by the type of reconstruction
algorithm used (Filtered Back Projection, OSEM, etc.)
7.2.2. Quality  control  of  the
registration/fusion/segmentation  software
Segmentation of the volumes of interest can be performed
with a dedicated workstation designed for this purpose (the
Contouring Workstation). Alternatively, the radiotherapy TPS
can also be used. The objective of the quality control tests
in this section is to assure that the radiation oncologist
has received the correct data needed to prescribe treatment
and reliably delineate the targets. Data integrity and spatial
integrity should both be veriﬁed:
• Data transfer. The systems used to transfer data must be
checked for compatibility to ensure that all data from the
copied ﬁle is transferred completely, either to the hard disk
or to the DICOM transfer nodes of the hospital network.
Check that the information from the DICOM attributes and
the digital matrix of the image  are both maintained so that
there is no loss of data due to conversion. Veriﬁcation should
include both series of images (from the CT and PET). When
purchasing new systems, it is advisable to demand compati-
bility between the PET-CT scanner and the TPS. Connectivity
between two pieces of equipment can be evaluated by the
use of the equipment’s DICOM Conformance Statements.
This is relevant to determine what type of information is
transmitted, especially when absolute quantiﬁcation of the
signal is important.
• Image  registration. This process consists of overlaying 2 or
more  images of the same scene either acquired at different
times and/or from different angles, and, frequently, with
different sensors. Before fusion can be performed, the pixels
from all images must be matched one-to-one. This involves
a series of transformations: turns, scaling, and, at times,
deformations (Fig. 8).
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In hybrid PET-CT scanners, the hardware is used to perform
registration. In each imaging modality, registration is based on
the relative movement  of the patient to the detectors within
a known range. In an ideal world, image  registration would
be perfectly precise if the following conditions were true: the
patient remains completely immobile; the table top is not
deformed by weight and is moved precisely between the coor-
dinates deﬁned for each modality; and the CT and PET imaging
planes are exactly parallel to each other and perpendicular
to the table top. Unfortunately, this is not the case in actual
practice. For this reason, the purpose of veriﬁcation testing is
to evaluate the degree of misalignment to determine its effect
on the geometric margins that need to be applied to the con-
toured PET volumes. Quantiﬁcation of this discrepancy should
be considered a systematic error. The aim of this type of test
is similar to that described above for the end-to-end test (i.e., to
verify alignment between the CT and PET) except that, in this
case, we evaluate the images on the Contouring Workstation.
To simulate the patient load, we must add weight—the IAEA
recommends adding 100 kg—to the table top.54
Accuracy of the fusion algorithms. Fusion involves syn-
thesizing the data provided by the different images into a
single set of data. Fusion is not exclusive to PET-CT imaging,
as it is performed in all imaging modalities (MRI and ultra-
sound, among others). Due to qualitative differences in the
data, registration is more  complicated when different types of
images are co-registered. A rigid phantom is used to quantify
the error generated by the fusion algorithms (mutual informa-
tion, etc.). In deformable geometries, quantiﬁcation is difﬁcult
due to the lack of simple analytical tools and also because
all deformable registration methods have a limited range of
applicability, either because they were designed only for spe-
ciﬁc cases (e.g., 4D) or due to a lack of a consistent physical
model (e.g., deformation of bone tissue as if it were soft tissue).
In all cases, these tests should be performed by a well-trained
expert to avoid generating a larger error than the one being
corrected.
Precision of segmentation tools. Automated segmenta-
tion tools (by threshold, gradient, etc.) for the PET image
should also be checked to verify that these perform exactly
as expected. For example, these tools should not introduce
any information not contained in the original image  (via soft-
ening or enhancement ﬁlters, for instance) and there should
be no hidden signal correctors. Likewise, check to be sure that
there is no loss of the absolute signal due to normalization
in percentages. To counter the PVE, approximate mathemati-
cal methods can be used, although these must ﬁrst be veriﬁed
with simple geometric ﬁgures (following manufacturer speci-
ﬁcations). Note that if these veriﬁcation tools are not available
in the software package, the dimensions of small or elongated
volumes may be underestimated. It is important to verify that
the tumour image  identiﬁed by the automated segmentation
process can be exported to a DICOM format that is compati-
ble with the TPS used in RT planning. Although workstations
in the Department of Nuclear Medicine allow for deﬁnition of
the ROI based on a predetermined minimum level of intensity,
the resulting image  is, unfortunately, not compatible with the
software used in Radiation Oncology.
Accuracy of the quantiﬁcation tools. The system should
be capable of providing quantitative information from bothiotherapy 1 7 ( 2 0 1 2 ) 298–318
the CT and the PET. This includes statistical data about the
volumes, ROIs (mean, deviation, histograms, etc.) as well as
the pixel values in Hounsﬁeld units (the most common) and
radioactivity concentration (kBq/ml) and, if possible, for SUV
uptake. As described in the previous section, if the uptake
volumes are too small, the PVE will distort SUV values; the
impact of PVE is thus particularly relevant for small volumes.
Veriﬁcation should be performed with known patterns, either
by calibrated sources or tracer quantities that have been cali-
brated (by in-house dose calibrators) in phantoms with known
geometries and different ranges of background activity. In
all cases, the traceability of the measuring chain should be
veriﬁed.41
Archive and security copies.  Verify that archiving and copy-
ing actions are performed accurately and that it is possible to
recover data from a historical patient in a reasonable amount
of time without undue difﬁculty. For permanent storage in
a PACS, assure compatibility of the PACS and the storage
integrity of the digital data.
7.2.3.  Quality  control  for  the  treatment  planning  system
Verify that the TPS includes the density table for the CT.
This seems obvious, but occasionally it is overlooked because
PET-CT units are often located in the Nuclear Medicine Depart-
ment.
DICOM-RT. RT structure set. If transferring images with
volumes that have been delineated on an external station,
verify that the volume has been transferred correctly.
7.2.4.  Radiopharmaceutical  dispensing  unit/dose
calibrator
Calibration: obtaining the calibration factor for the dose cal-
ibrator. Because tools to measure radioactivity concentration
may not always be available, doses are sometimes dispensed
by volume. However, this can lead to large errors in dispensa-
tion. Any calibration errors will be transferred to the PET unit
and will therefore affect the kBq/ml of the pixel value if this is
used to determine the counts rate/activity (see sensitivity).
Detector stability test. Verify stability with a Cs-137 source
at the start of the day and check contamination throughout
the day (especially important when the scanner is used on
two consecutive both morning and afternoon).
7.2.5. Routine  and  periodic  testing  of  the  PET  and  CT
We used the data provided by Refs. 54 and 55,  which the
reader is encouraged to consult for more  details, to cre-
ate Tables 3 and 4, which describe the other quality control
tests-and the frequency thereof-that should be performed for
PET-CT scanners. These recommendations are general, and
not speciﬁc to radiotherapy. Finally, we  also recommend that
the reader consult the manufacturer’s PET-CT manual, which
can be used to adapt these tests to their particular situation
(i.e., based on available resources and scanner characteristics).
7.3.  Radiological  protection  for  patients  and  workersIt is important to assess the radiation level in the PET-CT room
and the dose received by the nuclear medicine and radiothe-
rapy technologists as well as the patients.
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Table 3 – Routine tests and frequency thereof for the PET scanner.
PET
Daily Weekly Quarterly Annual
Detector stability check.
Inspect sinograms or
compare to a pattern.
Gain normalization
Quantiﬁcation scan
Compare ROI to
calibrated radioactivity
Calibration of photomultipliers
Coincidence Timing Resolution
Time of ﬂight
Normalization
Cross-calibration with the
well-counter
Uniformity
Resolution
Count  rate
Correction of dead time
losses
Sensitivity
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c.3.1. ALARA  criteria
LARA (“as low as reasonably achievable”) refers to the general
im of minimizing the radiation dose to workers and patients.
he RT technologist should be aware that patients undergo-
ng planning PET-CT have been injected with a radionuclide
nd are, therefore, a source of external radiation and con-
amination. To reduce exposure time, it is essential that
echnologists prepare thoroughly and carefully before com-
ng into contact with the patient. The use of shoes, gloves,
nd disposable aprons all help to minimize contact-related
ontamination.
Following ALARA criteria, all immobilization devices,
ncluding thermoplastic or vacuum-moulded devices, should
e prepared before radiopharmaceutical administration. The
atient can be repositioned in the PET-CT unit after injection.
ecause it takes longer to reposition and align a previously tat-
ooed patient after radiopharmaceutical injection than it does
o place the radiopaque markers and mark their position, it
ay be preferable to apply the deﬁnitive tattoo after comple-
ion of the imaging study, when radioactivity has diminished.
The nuclear medicine technologist should be aware that
he patient will receive RT treatment based on the geometry
nd the coordinate origins established during image  acquisi-
ion, and he or she should be familiar with the language and
echniques used in this process.
There is a very real possibility of contamination during
he imaging study (e.g., through vomiting or urine loss) and
ll staff should be trained and prepared for such events in
rder to contain the contamination. Appropriate decontam-
nation material should be on hand, including contamination
etectors. If the equipment becomes contaminated, decon-
amination may be needed before any other imaging studies
an be performed.
Table 4 – General tests and frequency for CT.
CT
Daily Weekly Annual
Water density
Artefacts
Uniformity
Linearity of
attenuation
coefﬁcients
Low-contrast
resolution
Calibration of
Hounsﬁeld
numbers
Laser alignment
Position of slice
Slice thickness
Dosimetry CTDI
Resolution
Low-contrast resolution
Dosimetry CTDI
Table warpingQuantiﬁcation
Table movement
The use of protective clothing is not effective against
energy annihilation photons (511 keV) because the thickness
of the lead typically used in this material is insufﬁcient (up to
90% of photons penetrate the material).
The use of comprehensive checklists before and during
the PET-CT scan can reduce exposure time and minimize the
likelihood of errors, which will also reduce the probability of
having to repeat the scan. In addition, clear lines of communi-
cation between the Radiation Oncology and Nuclear Medicine
departments should be established to avoid errors in transmit-
ting information that could lead to improper administration
of the radiopharmaceutical.
7.3.2.  Pregnancy  and  lactation
The possibility that female patients of child-bearing age might
be pregnant must be considered. The risks and beneﬁts of the
scan should be thoroughly discussed with pregnant patients.
Patients who are breast-feeding should be instructed to inter-
rupt feeding for at least 18.5 h (10 half-lives of decay). Most
of the radiation dose to the baby is caused by external radia-
tion rather than ingestion through breast-feeding.56 It is the
responsibility of the physician to explain this information to
the patient before she signs the informed consent form.
7.3.3.  Children
Due to their relatively small size, children may absorb more
radiation from the CT scan than from the radiopharmaceu-
tical. For this reason, it is important to develop protocols for
image acquisition that minimize the CT dose without com-
promising image  quality.
7.3.4.  Dose  to  workers
All staff involved in handling patients should be provided with
lapel, wrist, and ring dosimeters if necessary. Pregnant work-
ers should have an abdominal dosimeter to insure that the
dose to the foetus does not exceed the annual dose limit to
the public (1 mSv).
Fig. 9 shows a sample of doses measured with a 0.5 l camera
at 10 cm and 1 m at the Hospital Universitario La Paz (Spain).
Values are also shown for dosimeters located in the pocket of
the RT technologist during patient immobilization on the PET
table; patient dose is about 7 Sv/patient in this same hospital.To obtain reference values, it is important to quantify the
dose received by patients as a function of the acquisition
technique and the radioactivity of the radiopharmaceutical.34
Fig. 10 shows the typical dose in different phases during FDG
316  reports of practical oncology and rad
Fig. 10 – Dose received by the patient at various stages
To date, no ideal segmentation method has been estab-during a PET/CT imaging study with contrast media.
contrast-enhanced PET/CT, with a topogram, low dose CT, PET,
and intravenous contrast CT.
7.4.  Stafﬁng  needs
The medical physicist is responsible for carrying out the tests
described above and this should be indicated in the Radio-
therapy Quality Assurance Program. However, the relevant
scientiﬁc societies need to collaborate to establish standard-
ized tests.
8. Psychological  impact  and  patient  safety
8.1.  Psychological  impact
The gantry aperture of the PET-CT simulator is generally
smaller than that of the CT-simulator. PET image  acquisition
also requires more  time. These two factors make PET-CT more
uncomfortable for the patient. Greater discomfort, in turn,
implies a higher risk of movement, more  muscle tension, agi-
tated breathing, etc. Another potential cause of discomfort is
the fact that patients must disrobe completely; for this rea-
son, every effort should be made to minimize patient nudity.
These and other methods designed to reduce the psychologi-
cal impact on patients deserve serious consideration.
An important component of patient preparation involves
providing sufﬁcient information about the procedure before
it begins. The main points that should be explained are the
following:
• What a PET/CT is and how it works.
• Why PET-CT-Simulation is required.
• The approximate duration of the procedure.
• How to prepare for the procedure: fasting, medications, rec-
tum and bladder status, exercise, dental prostheses, etc.
• The size of the gantry aperture of the PET-CT.
• The position that the patient must maintain.
• The immobilization devices to be used; if thermoplastics
will be used, explain their use.
• Where and why tattoos and/or marks will be made.
• How to breathe in a relaxed and regular manner.
• Muscle relaxation and thought distraction techniques that
can be used before and during the procedure.It would be helpful to create a brochure that contains all of
this important information.iotherapy 1 7 ( 2 0 1 2 ) 298–318
8.2. Patient  safety
During a diagnostic PET-CT scan, patient-operator communi-
cation via interphone is quite easy. However, when immobi-
lization devices are used (as in planning PET-CT)—particularly
head and neck devices such as the thermoplastic masks or
bite blocks—communication may be difﬁcult. Moreover, head
& neck patients often have compromised phonation caused
by surgery or by the tumour itself. Consequently, to reduce
patient anxiety and guarantee a quick response to any unex-
pected problems, it is essential that the patient have easy
access to an emergency button or that he/she be given clear
instructions to raise a hand if any problems arise. Likewise, to
assure that the patient is monitored throughout the entire pro-
cedure, the availability and use of a closed-circuit television,
such as those used in RT treatment rooms, is recommended.60
Special attention should be paid to assuring permeability
of the IV cannula used for contrast infusion. Similarly, the
infusion pump should be checked to make certain that it is
working properly. Extravasation or inadequate infusion could
compromise the quality of the CT images or cause patient
movement  due to pain at the IV insertion point; in both of
these scenarios, the scan would have to be repeated. For this
reason, a test bolus with saline solution (a feature of all mod-
ern contrast injectors) should be administered. Before the IV
contrast is administered, it is important to check the patient’s
medical record for allergies to contrast agents, proper kidney
function (serum creatinine levels), and nephrotoxicity risk fac-
tors (e.g., diabetic or hypertensive nephropathy, nephrectomy,
recent administration of IV contrast agents or nephrotoxic
drugs).
Although unexpected allergic reactions to contrast agents
are uncommon, the limited ability of immobilized patients
to communicate easily makes continuous monitoring of
the patient essential. It is therefore especially important to
observe skin colouration and respiratory rate, and to watch
for unexpected movements of the extremities or gestures that
could be interpreted as signs of anxiety, discomfort, or suffer-
ing (e.g., grabbing the table, agitation, hitting with hands or
feet, etc.).
9.  Conclusions
The true utility of PET-CT in the RT planning process is still
unclear. Standardization of the technique will allow us to com-
pare clinical results and approaches from different centres
before ﬁnal validation.
For hospitals who wish to implement planning PET-CT for
RT, it is essential to ﬁrst develop—through interdepartmental
collaboration—a well-deﬁned protocol. Similarly, it is essential
to verify that all equipment needed to carry out the imaging
study is available. All equipment used in the RT planning pro-
cess should be checked and “tuned-up” to assure high quality
and reliable diagnostic images and to offer the maximum
radiological safety to the patient and staff.lished. Consequently, each clinical group must select the
method they consider to be the most reliable and with
which they are most familiar. Regardless of the segmentation
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eﬁnitively establish the role of metabolic imaging in radio-
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